Literature DB >> 23611112

A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice.

Norihiro Kubota1, Shoichi Kado, Mitsuyoshi Kano, Norie Masuoka, Yuriko Nagata, Toshihide Kobayashi, Kouji Miyazaki, Fumiyasu Ishikawa.   

Abstract

The aim of the present study was to establish a progressive steatohepatitis mouse model because few reported animal models of non-alcoholic steatohepatitis (NASH) show the progression from fatty liver to steatohepatitis. C57BL/6N mice were fed a high-fat diet (HFD) to develop obesity and were either administered carbon tetrachloride (CCl4 ) eight times (0.05 mL/kg, s.c., once, followed by 0.1 mL/kg, s.c., seven times) or not. Serum parameters and hepatic histopathology were examined. In a separate experiment, CCl4 was administered subcutaneously from 0 to eight times to HFD-fed obese mice to investigate progressive changes. Markers of oxidative stress, inflammation and apoptosis, as well as histopathological changes in the liver, were analysed. The HFD-fed obese mice showed fatty liver but not steatohepatitis. In contrast, HFD-fed mice administered CCl4 eight times showed histopathological features of steatohepatitis (fatty liver, inflammation, hepatocellular ballooning and fibrosis) and increased serum alanine aminotransferase levels. However, the multiple administration of CCl4 to obese mice reduced the ratio of reduced glutathione to oxidized glutathione, superoxide dismutase activity and mitochondrial DNA copy number, leading to the development of chronic oxidative stress, increased numbers of apoptotic cells and increased levels of both tumour necrosis factor-α and transforming growth factor-β mRNA. The resulting inflammation led to increased hydroxyproline content in the liver and fibrosis. The present study demonstrates that multiple administration of CCl4 to HFD-fed obese mice induces chronic oxidative stress that triggers inflammation and apoptosis and leads to the development of fibrosis in the liver, resulting in progression from fatty liver to steatohepatitis. This murine model will be useful in the research of hepatic disorders.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23611112     DOI: 10.1111/1440-1681.12102

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  23 in total

1.  A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Authors:  Lichen Bao; Jun Yin; Wen Gao; Qun Wang; Wenbing Yao; Xiangdong Gao
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

2.  Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.

Authors:  Hualing Xiao; Peng Li; Xiaolin Li; Haiying He; Jianhua Wang; Fengxun Guo; Jiliang Zhang; Luxia Wei; Hongmei Zhang; Yueyuan Shi; Lijuan Hou; Liang Shen; Zhengxia Chen; Chunyan Du; Shouliang Fu; Pengtao Zhang; Fei Hao; Ping Wang; Deming Xu; Wei Liang; Xin Tian; Aiming Zhang; Xingdong Cheng; Ling Yang; Xiangjian Wang; Xiquan Zhang; Jian Li; Shuhui Chen
Journal:  ACS Med Chem Lett       Date:  2017-10-31       Impact factor: 4.345

Review 3.  Animal models of drug-induced liver injury.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-03       Impact factor: 5.187

4.  Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment.

Authors:  Seol Hwa Seo; Eunhwan Kim; Minguen Yoon; Soung-Hoon Lee; Byung-Hyun Park; Kang-Yell Choi
Journal:  Exp Mol Med       Date:  2022-09-16       Impact factor: 12.153

Review 5.  Characterization of diet based nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in rodent models: Histological and biochemical outcomes.

Authors:  Ghaidafeh Akbari; Seyyed Ali Mard; Feryal Savari; Barat Barati; Maryam J Sameri
Journal:  Histol Histopathol       Date:  2022-04-27       Impact factor: 2.130

6.  Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice.

Authors:  Nisreen Soufi; Angela M Hall; Zhouji Chen; Jun Yoshino; Sara L Collier; James C Mathews; Elizabeth M Brunt; Carolyn J Albert; Mark J Graham; David A Ford; Brian N Finck
Journal:  J Biol Chem       Date:  2014-09-11       Impact factor: 5.157

7.  Use of a convolutional neural network and quantitative ultrasound for diagnosis of fatty liver.

Authors:  Trong N Nguyen; Anthony S Podkowa; Trevor H Park; Rita J Miller; Minh N Do; Michael L Oelze
Journal:  Ultrasound Med Biol       Date:  2020-12-25       Impact factor: 2.998

8.  A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.

Authors:  Takuma Tsuchida; Youngmin A Lee; Naoto Fujiwara; Maria Ybanez; Brittany Allen; Sebastiao Martins; M Isabel Fiel; Nicolas Goossens; Hsin-I Chou; Yujin Hoshida; Scott L Friedman
Journal:  J Hepatol       Date:  2018-03-21       Impact factor: 30.083

Review 9.  Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide.

Authors:  Mikhaïl A Van Herck; Luisa Vonghia; Sven M Francque
Journal:  Nutrients       Date:  2017-09-27       Impact factor: 5.717

10.  Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid.

Authors:  Nanlin Zhu; Suling Huang; Qingli Zhang; Zhuohui Zhao; Hui Qu; Mengmeng Ning; Ying Leng; Jia Liu
Journal:  Metabolites       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.